期刊文献+

琥珀酸美托洛尔缓释微丸型片剂的制备与体外释放度考察 被引量:6

Preparation and in vitro Release of Metoprolol Succinate Sustained-release Pellet Tablets
下载PDF
导出
摘要 目的制备琥珀酸美托洛尔缓释微丸型片剂,并对其体外释放度进行考察。方法采用流化床包衣法制备琥珀酸美托洛尔缓释微丸,将缓释微丸与适合的辅料混合后采用直接压片法制备琥珀酸美托洛尔微丸型片剂,并采用f2相似因子法评价自制制剂和参比制剂在释放介质中的体外释放行为。结果选用空白蔗糖丸芯粒径为250~350μm,以Kollicoat SR 30D为微丸的衣膜材料,包衣增重为20%,增塑剂用量为20%,滑石粉用量为50%,压片压力为80 kN时,自制制剂和参比制剂f2相似因子值大于50,说明2种制剂体外释放行为相似。结论制备的琥珀酸美托洛尔缓释微丸型片剂的释药行为较好,有望应用于工业生产。 Objective To prepare metoprolol succinate sustained-release pellet tablets,and to investigate their in vitro drug release behavior. Methods Metoprolol succinate sustained-release pellets were prepared by fluid bed coating technology,while the sustained-release pellet tablets were prepared by direct compression of sustainedrelease pellets and suitable excipients. The release behavior similarity was investigated between the reference and self-prepared tablets in release media. Similar factor( f2) was used to evaluate the similarity of release curves. Results The size of blank sugar pellets was 250- 350 μm. With Kollicoat SR 30 D as the coating material,the coating level was 20%,the plasticizer content was 20%,the anti-tacking agent content was 50%,and the tableting pressure was 80 kN. The value of f2 was more than 50,and the release behavior was similar. Conclusion The release behavior of metoprolol succinate sustained-release pellet tablets is quite satisfactory. This method of preparation may be used in industrial production.
出处 《解放军药学学报》 CAS 2014年第4期299-302,共4页 Pharmaceutical Journal of Chinese People's Liberation Army
关键词 琥珀酸美托洛尔 缓释微丸 微丸压片 metoprolol succinate sustained-release pellet tableting of pellets
  • 相关文献

参考文献6

  • 1李军,杨慧玲.美托洛尔新剂型——倍他乐克缓释片[J].中南药学,2007,5(6):571-573. 被引量:14
  • 2Sandberg A, Ragnarsson G, Jonsson UE, et al. Design of a new multiple unit controlled release formulation of metoprolol-metoprol- ol CR[ J]. Eur J Clin Pharmacol, 1988,33 (Suppl) : S3 - S7.
  • 3Bodmeier R. Tableting of coated pellets [ J ]. Eur J Pharm Biop- harm,1997,43(1) :1 -8.
  • 4高春生,梅兴国.微丸压片技术的研究进展[J].中国药学杂志,2006,41(3):163-166. 被引量:11
  • 5Langly N, Lan Y. How to make oral dosage coatings count [ EB/ OL]. PFQ, June 2009. (http ://www. pharmaquality, com).
  • 6Lecomte F, Siepmann J, Walther M, et al. Ploymer blends used for the aqueous coating of solid dosage forms : importance of the type of plasticizer [ J ]. J Control Ralease, 2004,99 ( 1 ) : 1 - 13.

二级参考文献33

  • 1[1]Wikstrand J,Warnold I,Olsson G,et al.Primary prevention with metoprolol in patients with hypertension.Mortality results from the MAPHY study[J].JAMA,1988,259(13):1976-1982.
  • 2[2]Olsson G,Tuomilehto J,Berglund G,et al.Primary prevention of sudden cardiovascular death in hypertensive patients.Mortality results from the MAPHY Study[J].Am J Hypertens,1991,4(2 Pt 1):151-158.
  • 3[3]Olsson G,Wikstrand J,Warnold I,et al.Metoprolol-induced reduction in postinfarction mortality:pooled results from five double-blind randomized trials[J].Eur Heart J,1992,13(1):28-32.
  • 4[4]Sandberg A,Ragnarsson G,Jonsson UE,et al.Design of a new multiple-unit controlled-release formulation of metoprolol-metoprolol CR[J].Eur J Clin Pharmacol,1988,33(Suppl):S3-7.
  • 5[5]Kendall MJ,Maxwell SR,Sandberg A,et al.Controlled release metoprold.Clinieal pharmacokinetic and therapeutic implications[J].Clin Pharmacokinet,1991,21(5):319-30.
  • 6[6]Wieselgren I,Lundborg P,Sandberg A,et al.Pharmacokinetic and pharmacodynamic evaluation of metoprolol controlled release (CR/ZOK)50 mg in young subjects[J].J Clin Pharmacol,1990,30(2 Suppl):S28-32.
  • 7[7]Sandberg A,Blomqvist I,Jonsson UE,et al.Pharmacokinetic and pharmacodynamic properties of a new controlled-release formulation of metoprolol:a comparison with conventional tablets[J].Eur J Clin Pharmacol,1988,33(Suppl):S9-14.
  • 8[8]Lucker P,Moore G,Wieselgren I,et al.Pharmacokinetic and pharmacodynamic comparison of metoprolol CR/ZOK once daily with conventional tablets once daily and in divided doses[J].J Clin Pharmaeol,1990,30(2 Suppl):S17-27.
  • 9[9]Darmansjah I,Wong E,Setiawati A,et al.Pharmacokinetic and pharmacodynamic properties of controlled release(CR/ZOK)metoprolol in healthy Oriental subjects:a comparison with conventional formulations of metoprolol and atenolol[J].J clin Pharmacol,1990,30(2 Suppl):S39-45.
  • 10[10]Smith SC Jr,Blair SN,Bonow RO,et al.AHA/ACC Scientific Statement:AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease:2001 update:A statement for healthcare professionals from the American Heart Association and the American College of Cardiology[J].Circulation,2001,104(13):1577-1579.

共引文献23

同被引文献94

引证文献6

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部